Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.96 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.96 |
| ▸ | ALPI | P09923 | 1/20 | 0.96 |
| ▸ | PKM | P14618 | 1/20 | 0.96 |
| ▸ | XIAP | P98170 | 1/20 | 0.96 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.67 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.67 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.67 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL11103233 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| D-Phenylalanine SCHEMBL503309 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1449124 | 0.98 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL8118 | 0.98 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL15671104 | 0.98 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23159186 | 0.98 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1331985 | 0.98 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL16398197 | 0.98 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| D-Phenylalanine SCHEMBL837632 | 0.98 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL385804 | 0.98 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 401 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680629-A1 | STAPLED PEPTIDES | The Florey Institute Of Neuroscience And Mental Health (AU) | 2026-01-21 | — | — | EP | claimed |
| WO-2024187241-A1 | STAPLED PEPTIDES | THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH (AU) | 2024-09-19 | — | — | WO | claimed |
| US-11976137-B2 | Compounds for use as apelin receptor antagonists | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-05-07 | — | — | US | claimed |
| US-11566057-B2 | Long-acting co-agonists of the glucagon and GLP-1 receptors | MERCK SHARP & DOHME LLC (US) | 2023-01-31 | — | — | US | claimed |
| US-11492385-B2 | Long-acting co-agonists of the glucagon and GLP-1 receptors | MERCK SHARP & DOHME LLC (US) | 2022-11-08 | — | — | US | claimed |
| US-20210155659-A1 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2021-05-27 | — | — | US | claimed |
| EP-3773663-A1 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | Cambridge Enterprise Limited (GB) | 2021-02-17 | — | — | EP | claimed |
| US-20200392196-A1 | LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | claimed |
| US-10793615-B2 | Long-acting co-agonists of the glucagon and GLP-1 receptors | MERCK SHARP & DOHME CORP. (US) | 2020-10-06 | — | — | US | claimed |
| EP-3700550-A1 | LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | Merck Sharp & Dohme Corp. (US) | 2020-09-02 | — | — | EP | claimed |
| US-20200270325-A1 | LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2020-08-27 | — | — | US | claimed |
| CN-111132690-A | Long-acting co-agonists of glucagon and GLP-1 receptor | 默沙东公司 | 2020-05-08 | — | — | CN | claimed |
| US-20190338008-A1 | LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME LLC | 2019-11-07 | — | — | US | claimed |
| WO-2019193355-A1 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | DAVENPORT ANTHONY PETER (GB) | 2019-10-10 | — | — | WO | claimed |
| WO-2019060660-A1 | LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2019-03-28 | — | — | WO | claimed |
| EP-3377521-A2 | LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | Merck Sharp & Dohme Corp. (US) | 2018-09-26 | — | — | EP | claimed |
| WO-2017074798-A2 | LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | claimed |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-4435571-A | 5-(Substituted benzyl)-6-oxo-2-piperazine carboxylic acids and esters | RICHARDSON MERRELL INC. (US) | 1984-03-06 | — | — | US | disclosed |
| US-4341698-A | Enkaphalin derivatives | RICHARDSON-MERRELL INC. (US) | 1982-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492385-B2 | Long-acting co-agonists of the glucagon and GLP-1 receptors | GLP1R, GCGR, GIPR | SLC7A5 3291/4885PTGS1 1221/4885ALPI 1169/4885 |
| US-11976137-B2 | Compounds for use as apelin receptor antagonists | APLNR, GIPR, GRPR | SLC7A5 2343/4885PTGS1 1137/4885ALPI 1061/4885 |
| US-11566057-B2 | Long-acting co-agonists of the glucagon and GLP-1 receptors | GLP1R, GCGR, GIPR | SLC7A5 3291/4885PTGS1 1221/4885ALPI 1169/4885 |
| US-20210155659-A1 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | APLNR, GIPR, GRPR | SLC7A5 2343/4885PTGS1 1137/4885ALPI 1061/4885 |
| US-20200270325-A1 | LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | GLP1R, GCGR, GIPR | SLC7A5 3291/4885PTGS1 1221/4885ALPI 1169/4885 |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, IL36G | SLC7A5 1439/4885PTGS1 1487/4885ALPI 1053/4885 |
| US-10793615-B2 | Long-acting co-agonists of the glucagon and GLP-1 receptors | GLP1R, GCGR, GIPR | SLC7A5 3291/4885PTGS1 1221/4885ALPI 1169/4885 |
| US-20200392196-A1 | LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | GLP1R, GCGR, GIPR | SLC7A5 3291/4885PTGS1 1221/4885ALPI 1169/4885 |
| US-20190338008-A1 | LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | GLP1R, GCGR, GIPR | SLC7A5 3291/4885PTGS1 1221/4885ALPI 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.